Biomimetic cartilage nanofiber tissue scaffold

A biomimetic scaffold using PCL, gelatin, and hyaluronic acid with DF-MSCs and TGF-β1 addresses the limitations of existing cartilage repair methods by enhancing regeneration and mechanical strength, offering a biocompatible, biodegradable solution for cartilage repair.

WO2026235654A1PCT designated stage Publication Date: 2026-11-12MUGLA SITKI KOCMAN UNIVERSITESI REKTORLUGU
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/TR2025/052023
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-12-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing cartilage repair methods are inadequate in terms of mechanical strength, regeneration time, cost, immune response, infection risk, and applicability, failing to fully reconstruct natural hyaline cartilage and requiring improvements in tissue engineering.

Method used

A biomimetic tissue scaffold composed of PCL, gelatin, and hyaluronic acid, encapsulating DF-MSCs and TGF-β1, is developed to mimic natural cartilage, enhance cell attachment, and promote chondrogenic differentiation, with a three-dimensional porous structure for improved regeneration.

Benefits of technology

The scaffold accelerates cartilage regeneration, provides mechanical compatibility, and supports long-term regenerative treatment with high biocompatibility and biodegradability, facilitating clinical use and functional cartilage formation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure TR2025052023_12112026_PF_FP_ABST
    Figure TR2025052023_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomaterials, tissue engineering, and regenerative medicine, and in particular to a tissue scaffold developed for use in orthopedic and cartilage tissue repair applications, and to a method for producing the same.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] BIOMIMETIC CARTILAGE NANOFIBER TISSUE SCAFFOLD

[0002] TECHNICAL FIELD

[0003] The invention relates to the technical field of biomaterials, tissue engineering, and regenerative medicine, and in particular to a tissue scaffold developed for use in orthopedic and cartilage tissue repair applications, and to a method for producing the same.

[0004] PRIOR ART

[0005] Cartilage tissue is an elastic structure that covers the ends of bones on joint surfaces and provides protection against mechanical loads. However, due to its avascular nature and low cellular regeneration capacity, its ability to self-repair is extremely limited. Cartilage damage generally occurs due to trauma, aging, genetic predisposition, obesity, and joint diseases such as osteoarthritis. Such damage leads to joint stiffness, pain, and limitation of movement, thereby significantly reducing the quality of life of patients. In this context, existing techniques for cartilage repair can be examined under three main categories: temporary methods, corrective methods, and reinforcing methods.

[0006] Temporary methods are techniques that generally aim to alleviate the symptoms of cartilage damage but do not provide permanent tissue regeneration. The arthroscopic debridement method relieves pain by surgically removing damaged cartilage tissue. However, this method does not promote the formation of new cartilage and generally results in the development of low-quality fibrocartilage. In addition, steroid and hyaluronic acid injections are also among the frequently used temporary treatment methods. These injections can temporarily improve mobility by increasing lubrication in the joint. However, they do not provide cartilage regeneration in the long term, and their effects decrease over time.

[0007] Corrective methods include surgical or biomedical approaches aimed at promoting healing of the damaged area. The microfracture method promotes the migration of stem cells to the area by creating small holes to expose the bone marrow in the damaged region. However, the tissue formed by this method is fibrocartilage with low mechanical strength, which differs from natural hyaline cartilage. This is insufficient in terms of long-term durability. The mosaicplasty (osteochondral graft transfer - OAT) method involvestransplanting healthy cartilage tissue from another site to the damaged area. However, donor site morbidity and issues related to suitable tissue matching limit the applicability of this method. In addition, the transplanted cartilage tissue deteriorates over time due to mechanical loading.

[0008] Reinforcing methods generally include bioengineering-based approaches and tissue engineering techniques. The autologous chondrocyte transplantation (ACT) method involves harvesting chondrocytes from the patient, expanding them in a laboratory environment, and implanting them into the damaged area. However, in this method, the processes of cell adhesion and functional maturation take a long time, and the risk of surgical complications is high. In bioengineering approaches, nanofiber tissue scaffolds produced by methods such as electrospinning are used to support cell growth. However, in existing studies, there are still deficiencies that require improvement in terms of optimal biomechanical properties and cellular response.

[0009] Mesenchymal stem cells (MSCs) have strong potential in the healing of cartilage damage, as in the regeneration of various tissues. Due to their high regenerative capacity and multilineage differentiation potential, MSCs are considered an effective option for cartilage tissue repair. However, in clinical applications, the use of these cellular contributions is generally limited due to practical challenges such as freezing, thawing, logistical needs, and infrastructure requirements. In particular, the requirement for low-temperature storage for the preservation and transportation of MSCs leads to these processes being expertiseintensive and costly. As a result, these challenges hinder the widespread clinical use of MSCs.

[0010] All existing methods fail to fully achieve ideal cartilage regeneration due to various technical limitations. One of the primary limitations is the length of the treatment process. In current treatment methods, the self-regeneration process of cartilage tissue takes a considerable amount of time and often does not result in complete healing. This situation delays patients’ return to daily life and negatively affects their quality of life.

[0011] In addition, one of the major problems in cartilage regeneration is low mechanical strength. Fibrocartilage tissue obtained by conventional methods may fail in the long term because it cannot reach the mechanical load-bearing capacity of natural hyaline cartilage. Especially in regions exposed to high pressure on joint surfaces, this tissue deteriorates over time and the risk of disease recurrence increases.Immune responses and the risk of infection are also among the significant problems encountered by existing techniques. In allograft or autograft methods, the immune system’s potential to exhibit tissue rejection reactions can negatively affect the treatment process. In addition, the risk of infection after surgical procedures is high, which further complicates the treatment process for patients.

[0012] Finally, the costs and applicability of existing treatment methods are also among the important limitations. Stem cell-based therapies and bioengineering approaches are costly and impose certain limitations in clinical practice. In order for these methods to be widely used, production processes need to be made more economical and their clinical application needs to be facilitated.

[0013] In patent application numbered TR2018 / 11205, biocompatible, osteogenic, and osteoconductive biomimetic composite nanofiber tissue scaffolds composed of polycaprolactone (PCL), bovine gelatin (GE), and bovine hydroxyapatite (BHA) were produced by the electrospinning method for use in bone and cartilage tissue damage repair applications.

[0014] Patent application published under number EP2851096 A1 relates to a composition for repairing cartilage tissue, a method for producing the same, and its use. Said patent provides a composition for repairing cartilage tissue obtained by mixing collagen and hyaluronic acid using a dual-chamber syringe or a mixer, wherein the collagen has a diluted concentration of 5-60 mg / mL, excluding water or a physiological phosphate buffer solution, and the hyaluronic acid has a diluted concentration of 5-20 mg / mL, excluding water or a physiological phosphate buffer solution.

[0015] All of these techniques are insufficient in reconstructing the functional structure of natural hyaline cartilage. Moreover, these methods bring additional problems such as high cost, long rehabilitation processes, and donor site morbidity. These limitations increase the need for next-generation biomaterials and tissue engineering approaches.

[0016] BRIEF DESCRIPTION OF THE INVENTION

[0017] The present invention relates to a tissue scaffold developed in particular for use in the treatment of orthopedic and cartilage tissue damage, and to a method for producing the same, in order to eliminate the disadvantages mentioned above and to provide new advantages to the relevant technical field.An objective of the present invention is to provide a tissue scaffold exhibiting high biocompatibility, porosity, and shape conformity, capable of mimicking the functional structure of natural hyaline cartilage.

[0018] Another objective of the present invention is to provide a structure that increases cell attachment and regeneration efficiency by enabling the direct integration of cells during the nanofiber production stage.

[0019] Another objective of the present invention is to accelerate the regeneration process and provide an innovative approach to tissue engineering by benefiting from the chondrogenic differentiation capacity of DF-MSCs and integrating the cells directly into the nanofibers during the production stage.

[0020] An objective of the present invention is to provide a tissue scaffold that facilitates clinical use while preserving the biocompatibility, biodegradability, and regenerative properties of mesenchymal stem cells (MSCs).

[0021] Another objective of the present invention is to create a tissue scaffold structure capable of preserving cell viability through the use of a biodegradable carrier matrix comprising poly(e-caprolactone) (PCL), gelatin (GEL), and hyaluronic acid (HA).

[0022] An objective of the present invention is to provide a nanofiber scaffold that enables the regenerative treatment of cartilage damage by presenting a carrier matrix structure enriched with biological agents such as dental follicle-derived mesenchymal stem cells (DF-MSCs) and Transforming Growth Factor Beta 1 (TGF-pi).

[0023] In order to achieve all of the objectives mentioned above and those that will become apparent from the detailed description below, the present invention is a biomimetic tissue scaffold comprising PCL, gelatin, and hyaluronic acid, encapsulating DF-MSCs and TGF-P1. Accordingly, its novelty lies in comprising a three-dimensional, highly porous, and biodegradable nanofiber structure containing dental follicle-derived mesenchymal stem cells and a growth factor. Thus, a treatment material is obtained that provides a long-term regenerative solution for cartilage damage, is similar to a natural matrix, facilitates cell infiltration, and is mechanically compatible.

[0024] An objective of the present invention is to provide a three-dimensional nanofiber tissue scaffold that mimics the natural extracellular matrix (ECM).Another objective of the present invention is to provide the production of three-dimensional, cotton-like, low-density nanofiber structures that exhibit superior performance compared to conventional two-dimensional membranes and that can be effective in the treatment of chronic and full-thickness cartilage defects.

[0025] BRIEF DESCRIPTION OF THE FIGURES

[0026] Figure 1 shows the FESEM image of the 3D nanofiber.

[0027] Figure 2 shows the porosity image of the 3D nanofiber obtained using the IMAGE-J program.

[0028] Figure 3 shows the fiber diameter distribution histogram of the 3D nanofiber obtained using the Origin-Pro program.

[0029] Figure 4-a shows the inverted microscope image of DF-MSCs at passage 0 (PO).

[0030] Figure 4-b shows the inverted microscope image of DF-MSCs at passage 1 (P1).

[0031] Figure 4-c shows the inverted microscope image of DF-MSCs at passage 2 (P2).

[0032] Figure 4-d shows the inverted microscope image of DF-MSCs at passage 3 (P3).

[0033] Figure 5 shows the flow cytometry analysis of positive surface markers of DF-MSCs.

[0034] Figure 6 shows the flow cytometry analysis of negative surface markers of DF-MSCs.

[0035] DETAILED DESCRIPTION OF THE INVENTION

[0036] In this detailed description, the invention relates to a tissue scaffold developed for use in the treatment of cartilage tissue damage and to a method for producing the same, and is explained by examples that are provided solely for a better understanding of the subject matter and that do not create any limiting effect.

[0037] The tissue scaffold of the invention comprises at least one biological agent and at least one matrix component within its structure.More specifically, the tissue scaffold consists of at least one matrix that provides a favorable microenvironment for cell attachment, proliferation, and differentiation, and at least one biological agent located within said matrix or matrices.

[0038] In the invention, the matrix is the fundamental component that both provides physical integrity for the tissue scaffold and creates a microenvironment suitable for cellular viability. For the tissue scaffold to be obtained, it provides mechanical strength, elasticity, and cell adhesion. In addition, it must also provide the targeted porosity characteristics for the tissue scaffold.

[0039] In the invention, the tissue scaffold comprises at least one of polycaprolactone, gelatin, and hyaluronic acid group components as the matrix.

[0040] In a preferred embodiment, the tissue scaffold comprises polycaprolactone as the matrix. Polycaprolactone, which has a semicrystalline and biodegradable nature, also contributes to maintaining the integrity of the scaffold throughout the regenerative process due to its slow degradation profile. On the other hand, polycaprolactone is also a material suitable for production by the electrospinning technique in the production method to be discussed later.

[0041] In a preferred embodiment, the tissue scaffold comprises gelatin as a matrix component. As is known in the art, gelatin is a polymer material derived from natural collagen and has very high biocompatibility. In the tissue scaffold of the present invention, it can be included as a matrix component particularly to benefit from this property. On the other hand, it provides favorable surface properties for biological activities of cells such as adhesion, spreading, and differentiation. At the same time, due to its hydrophilic structure, it has a high moisture retention capacity. By supporting cell proliferation and the adhesion of cells to the scaffold surface, it improves the interaction of the tissue scaffold with living cells.

[0042] In a preferred embodiment, the tissue scaffold comprises hyaluronic acid as a matrix component. Hyaluronic acid is included in the tissue scaffold in order to mimic the extracellular matrix, support cell proliferation, and improve the porosity structure through its water retention capacity. Hyaluronic acid is a glycosaminoglycan naturally present in cartilage tissue and, in tissue engineering applications, particularly supports the healthy growth of cells in a three-dimensional environment.In the most preferred embodiment, the matrix comprises hyaluronic acid, gelatin, and polycaprolactone together in order to obtain technical properties arising from their different structural characteristics.

[0043] When present together, the matrix comprises polycaprolactone in an amount ranging from 40% to 60% by weight, gelatin in an amount ranging from 40% to 60% by weight, and hyaluronic acid in an amount ranging from 0.5% to 2% by weight.

[0044] As mentioned previously, the tissue scaffold of the invention comprises one or more biological agents within its structure.

[0045] In a preferred embodiment, the biological agent comprises mesenchymal stem cells. Mesenchymal stem cells are stem cells having chondrogenic differentiation capacity and directly supporting the regeneration of cartilage tissue. Mesenchymal stem cells are included in order to achieve tissue regeneration through their capacity to directly differentiate into cartilage tissue (chondrogenic differentiation).

[0046] In the most preferred embodiment, the mesenchymal stem cells are dental follicle-based. Dental follicle-based mesenchymal stem cells offer higher chondrogenic potential compared to other mesenchymal stem cell sources and also possess osteogenic and neural differentiation capabilities. Due to these properties, the DF-MSCs integrated into the scaffold function as biological units that directly initiate the regeneration of cartilage tissue.

[0047] In a preferred embodiment, the biological agent comprises transforming growth factor beta-1 (TGF-pi). TGF-pi is one of the most effective growth factors in chondrogenesis and, by providing controlled release, can maintain its long-term effect within the target tissue microenvironment.

[0048] In a preferred embodiment, mesenchymal stem cells and TGF-pi are present together as biological agents. When TGF-pi and MSCs are present together as biological agents, the differentiation of MSCs into chondrocytes is rapidly and efficiently directed, and the formation of new cartilage tissue is promoted.

[0049] In the most preferred embodiment, the biological agents are encapsulated within the matrix. By encapsulating these components, controlled and localized release becomes possible, and the transmission of biological signals to the tissue is optimized. Thus, therapid degradation of the biological agents is prevented, and controlled differentiation of cells in a specific region is enabled.

[0050] The tissue scaffold characterized in this manner has a configuration that mimics the natural extracellular matrix. Due to its high porosity, it provides a suitable microenvironment for cell infiltration and nutrient-gas exchange. At the same time, owing to its low-density and compressible structure, it acquires a form that can be easily placed into full-thickness cartilage defects that are surgically difficult to access or have irregular geometry.

[0051] The tissue scaffold of the invention, by means of the production method to be characterized, possesses the technical solutions and advantages of having a three-dimensional structure compared to conventional two-dimensional tissue scaffolds. In this way, the tissue scaffold enables cells to grow and organize functionally in a manner similar to the natural tissue environment. This structure creates an effective microenvironment by providing a large surface area and depth for cell adhesion, migration, proliferation, and differentiation. The three-dimensional porous structure supports homogeneous distribution of cells within the scaffold, thereby increasing tissue integrity, while facilitating the circulation of nutrients and metabolic waste to maintain viable cells for a long period of time. In addition, since these structures can be mechanically compressed and shaped to conform to the defect region, they provide ease in surgical applications and increase the effectiveness of the regenerative process by exhibiting good integration with the target tissue.

[0052] In another aspect, the invention provides a method for obtaining the tissue scaffold characterized above. In this production method, electrospinning is used as the main technique. The process steps of the method of the invention are characterized below.

[0053] - Obtaining a solution comprising PCL

[0054] In a preferred embodiment, trifluoroethanol (TFE) is used as the solvent. TFE is a strong solvent capable of dissolving the matrix components described in the invention. It enables the precursor solution to have the desired homogeneous and viscosity values suitable for the electrospinning technique.

[0055] As the first process step, PCL is dissolved in TFE to prepare a solution. PCL is added to TFE in an amount ranging from 5% to 15% by weight. Mixing processes are carried outuntil a homogeneous mixture is obtained. In a preferred embodiment, this process is carried out for an average of 6 hours.

[0056] - Obtaining a solution comprising gelatin

[0057] As mentioned previously, since TFE is a good solvent, it is also used in obtaining the gelatin-containing solution.

[0058] In a preferred embodiment, gelatin in an amount ranging from 8% to 18% by weight is added to TFE, and mixing is carried out until a homogeneous mixture is obtained. In a preferred embodiment, this process is carried out for an average of 6 hours.

[0059] - Forming a new solution by combining the gelatin-containing solution and the PCL- containing solution

[0060] In a preferred embodiment, the gelatin-containing solution and the PCL-containing solution are combined in equal volume ratios. Mixing is carried out until the mixture becomes homogeneous.

[0061] - Adding hyaluronic acid to the newly obtained solution

[0062] Hyaluronic acid in solid form is added to the homogeneous mixture containing PCL and gelatin.

[0063] In a preferred embodiment, hyaluronic acid is added to this solution in an amount ranging from 1% to 5% by weight. The mixture containing these components is subjected to mixing until a homogeneous mixture is formed. In this way, hyaluronic acid can also be effectively dispersed within the other components.

[0064] As a result of all the processes, a solution comprising PCL, gelatin, and hyaluronic acid can be obtained.

[0065] - Adding mesenchymal stem cells to the obtained solution

[0066] In a preferred embodiment, the mesenchymal stem cells are obtained from dental cells by methods known in the art and are in solid form in a lyophilized state.Here, in order to specify the amount of mesenchymal stem cells, the total number of cells, which also has a corresponding meaning in the art, may be given. Accordingly, mesenchymal stem cells may be added in a number ranging between 0.5 million and 2 million per 1 mL volume of the solution (the solution containing PCL, HA, and gelatin is referred to).

[0067] By adding mesenchymal stem cells in this manner, the obtained solution may be subjected to mixing processes in order to achieve a homogeneous mixture. The mixing process is preferably carried out at low speeds, and its duration ranges from 10 to 20 minutes.

[0068] It is critical that no air bubbles form in the solution obtained during the mixing process. If air bubbles form, the efficiency of the subsequent electrospinning process may be reduced. In order to prevent this, the formed air bubbles are preferably removed in an ultrasonic bath.

[0069] - Obtaining a precursor mixture for the electrospinning process by adding the TGF- P1 component to the obtained solution

[0070] TGF-pi is added to the obtained mixture as another biological agent component. TGF-pi is a component in solid form and is added directly to this solution.

[0071] TGF-pi is added to 1 mL of the solution in an amount ranging from 10 to 50 ng. Subsequently, mixing processes are carried out to ensure the incorporation of the TGF-pi into the solution. This mixing process is preferably performed at low speeds, and its duration ranges from 10 to 20 minutes.

[0072] It is critical that no air bubbles form in the solution obtained during the mixing process. If air bubbles form, the efficiency of the subsequent electrospinning process may be reduced. In order to prevent this, the formed air bubbles are preferably removed in an ultrasonic bath.

[0073] - Feeding the obtained solution into an electrospinning syringe and obtaining the tissue scaffold structure by means of an electrospinning device

[0074] For the production of the target product from the solution obtained in the previous process steps, the electrospinning technique is used. In this form, the prepared solution constitutes an electrospinning solution. It is transferred into an electrospinning syringe in order to carry out the processes.In the electrospinning process, the syringe preferably has a 22-gauge blunt-ended needle and a volume of 5 cc.

[0075] A voltage in the range of 10 to 30 kV is applied to the electrospinning solution, and the flow rate is in the range of 0.1 to 0.5 mL / hour. The solution is sprayed onto a rotating bowlshaped collector to form the targeted nanofiber structure. The fibers accumulated on the collector surface are gathered in an unsqueezed, cotton-like, low-density, three-dimensional form; this structure is obtained as a biomimetic tissue scaffold having high surface area and porosity.

[0076] In order to demonstrate the effectiveness of the product obtained by the method characterized in the invention, characterization studies have been carried out. These tests are explained in more detail below.

[0077] First, surface morphology analyses of the obtained product were carried out. Figure 1 shows the FESEM image of the obtained tissue scaffold. Figure 2 shows the porosity appearance of the obtained tissue scaffold obtained using the IMAGE-J program.

[0078] Figure 3 shows the fiber diameter distribution histogram of the obtained product generated using the Origin-Pro program. According to this histogram, it is observed that the predominant fiber diameter falls within the range of 50-150 nm.

[0079] Another characterization study relates to the biodegradability of the obtained tissue scaffolds. In these tests, the initial dry weight of each tissue scaffold was measured, and the samples were then incubated in a centrifuged blood sample (platelet-rich plasma -PRP) in order to simulate the cellular environment, at a temperature of 37 ± 0.5 °C in an incubator. At weekly intervals, the samples removed from incubation had excess liquid removed using an air pump, after which the samples were dried again and their final weights were determined. The obtained data were analyzed using a standard formula used for calculating % mass loss ((initial weight - final weight) / initial weight x 100). As a result of the evaluation, it was determined that the tissue scaffolds underwent approximately 80% biodegradation at the end of the 80-day incubation period.

[0080] Another characterization study relates to the surface contact angle measurement of the obtained tissue scaffolds. These measurements were carried out using a Biolin Scientific Attension Theta Lite device. As a result of the analyses, it was determined that the tissue scaffolds exhibited low contact angle values and, in this respect, possessed hydrophilicproperties. The hydrophilic surface of the material supports more effective spreading and proliferation of cells within the matrix, indicating that the nanofiber structures in question can be successfully used in cartilage tissue engineering applications.

[0081] In another study, the chondrogenic differentiation capabilities of DF-MSCs included as components in the tissue scaffold are evaluated. In the in vitro culture studies carried out for this purpose, after the cells were seeded into 6-well plates, they were cultured for 3 weeks in a chondrogenic induction medium containing StemPro (Thermofisher). During this period, the culture medium was renewed every 3 days to support the differentiation of the cells in an appropriate microenvironment. At the end of the culture period, the adherent cells were fixed with 10% formaldehyde and stained with Alcian blue in order to determine the formation of chondrocyte-like cells. As a result of the staining, the nuclei of chondrocyte cells and the proteoglycans they produced were observed in blue, while cells showing cartilage- 1 ike differentiation were observed in dark blue; this confirmed that DF-MSCs possess chondrogenic differentiation capability. The obtained images were examined using a light microscope, and it was determined that the cells exhibited phenotypic characteristics specific to cartilage tissue. As a result of these procedures, Figure 4 shows that DF-MSCs formed fibroblast-like colonies. Figure 5 presents the flow cytometry analyses of the positive surface markers of DF-MSCs. It is observed that the positive markers (CD29, CD73, CD90, CD105) are expressed at levels above 95%. The results are presented together with isotype control antibodies (blue-colored histograms). Figure 6 presents the flow cytometry analyses of the negative surface markers of DF-MSCs. It is observed that the negative markers are expressed at levels below 2%. The analyses were performed by comparison with isotype control antibodies. One isotype control result is shown in the upper part.

[0082] In order to evaluate the effectiveness of the obtained tissue scaffolds in cartilage regeneration, an in vivo rat model was established. In the conducted studies, four separate experimental groups, each containing 6 rats, were defined. Within the scope of this study, an in vivo rat model was established to evaluate the effectiveness of the three-dimensional nanofiber tissue scaffolds developed in cartilage regeneration. In the study, four separate experimental groups, each containing 6 rats, were determined: Group G1 was the control group and no intervention was performed; in Group G2, a tissue scaffold containing cell-free PCL / GEL / HA was applied; in Group G3, a tissue scaffold containing PCL / GEL / HA with DF-MSCs was applied; and in Group G4, a tissue scaffold containing PCL / GEL / HA with both DF-MSCs and TGF-pi was applied. All subjects were prepared for surgery by administering Xylazine and Ketamine anesthetics intraperitoneally prior to the surgicalprocedure, and the knee joint was rendered suitable for surgery following antiseptic application. During the surgical intervention, the right genu joint was accessed via a medial paramedian incision, and a full-thickness cartilage defect with a diameter of 2.5 mm and a depth of 2 mm was created in the femoral medial condyle region using a microdrill. The tissue scaffolds prepared in accordance with the characteristics of each group were directly placed into this defect region. After the operation, the area was closed in a sterile manner and the comfort of the animals was ensured during the post-operative period. At the end of a six-week follow-up period, the animals were sacrificed, the femoral condyles were removed, and fixed in 10% formalin for histopathological analysis.This model was meticulously designed to compare the regenerative effectiveness of tissue scaffolds with different contents in a living organism and provides a controlled surgical and observation process. The applied method enables the acquisition of systematic data in terms of both biomaterial biocompatibility and contribution potential to tissue healing.

[0083]

[0084] Table 1. Histopathological findings of lesions formed in the tissue by the filling materialsThis analysis comparatively evaluates the histopathological effects of tissue scaffolds with different contents on cartilage defects and quantitatively reveals the success rates in tissue regeneration. According to the findings presented in Table 1, each group was treated with a specific type of filling material, and the effects of these materials on healing were examined based on parameters such as defect closure rate, presence of granulation tissue, and cartilage regeneration. The findings show that the highest level of tissue integrity and regeneration was achieved particularly in Group G4, in which cellular tissue scaffolds containing DF-MSCs and TGF-pi were applied. While the defect closure rate reached 100% in this group, healing at levels of 80-90% was also observed in the other cellular tissue scaffold groups. This demonstrates that both the biological content and the morphological characteristics of the tissue scaffold play a decisive role in the regeneration process, emphasizing that the more optimized the composition and cellular load of the filling material, the more successful the cartilage repair will be. These results indicate that the tissue scaffold structures obtained are capable of supporting functional cartilage formation in living organisms and have potential for clinical use.

[0085] The scope of protection of the invention is defined in the claims provided in the appendix and cannot be limited in any way to the examples described in this detailed description for illustrative purposes. Indeed, it is clear that a person skilled in the art may devise similar embodiments in light of the above descriptions without departing from the main concept of the invention.

Claims

CLAIMS1. A tissue scaffold developed for use in orthopedic and cartilage repair applications, characterized in that;it comprises at least one matrix and at least one biological agent,said matrix comprises at least one selected from the group consisting of polycaprolactone, hyaluronic acid, and gelatin,said biological agent comprises at least one selected from the group consisting of TGF-pi and mesenchymal stem cells.

2. A tissue scaffold according to claim 1 , characterized in that ;the matrix comprises polycaprolactone, hyaluronic acid, and gelatin together.

3. A tissue scaffold according to any one of the preceding claims, characterized in that;the biological agent comprises TGF-pi and mesenchymal stem cells together.

4. A tissue scaffold according to any one of the preceding claims, characterized in that;it has a three-dimensional structure and is compressible and shapeable so as to be suitable for placement in a defect region.

5. A method for obtaining a tissue scaffold suitable for use in orthopedic and cartilage repair applications, characterized in that;- it comprises the following process steps enabling the formation of a three- dimensional and porous structure:- preparing a solution comprising polycaprolactone,- preparing a solution comprising gelatin,- adding the prepared gelatin-containing solution to the obtained polycaprolactone-containing solution and mixing so as to obtain a homogeneous structure,- adding hyaluronic acid to the obtained solution,- adding mesenchymal stem cells to the obtained solution,- adding TGF-pi to the solution containing mesenchymal stem cells and obtaining an electrospinning solution by carrying out mixing processes,adding the obtained electrospinning solution to the syringe portion of an electrospinning device and obtaining the tissue scaffold by carrying out the electrospinning process.

6. A method according to claim 5, characterized in that; trifluoroethanol (TFE) is used as a solvent in the step of preparing the solution comprising polycaprolactone.

7. A method according to claim 6, characterized in that; polycaprolactone is added into TFE in an amount ranging from 5% to 15% by weight.

8. A method according to any one of claims 5 to 7, characterized in that;trifluoroethanol (TFE) is used as a solvent in the step of preparing the gelatincontaining solution.

9. A method according to claim 8, characterized in that; gelatin is added into TFE in an amount ranging from 8% to 18% by weight.

10. A method according to any one of claims 5 to 9, characterized in that; a solution is obtained by combining and mixing the gelatin-containing solution and the polycaprolactone-containing solution in equal volumes.

11. A method according to any one of claims 5 to 10, characterized in that; hyaluronic acid is added to the obtained solution in an amount ranging from 1% to 5% by weight.

12. A method according to any one of claims 5 to 11, characterized in that;mesenchymal stem cells are added in a number ranging from 0.5 million to 2 million per 1 mL of the solution.

13. A method according to any one of claims 5 to 12, characterized in that; TGF-pi is added to the solution containing mesenchymal stem cells in an amount ranging from 10 to 50 ng.

14. A method according to any one of claims 5 to 13, characterized in that; a voltage in the range of 10 to 30 kV is applied to the electrospinning solution.

15. A method according to any one of claims 5 to 14, characterized in that; the flow rate of the electrospinning solution is in the range of 0.1 to 0.5 mL / hour.